I just wonder if the new investor knows more than we old investors?
- anything about PBT2 deal negotiations, going on already close 3 years, the value estimations of PBT2 by different companies, not told to us
- anything about the many preclinical studies, with many patented molecules, not yet published
- anything more about Masters's license
- anything about the primate study, going on almost three years
- any results of the open ATH434 study, we are not informed
The biggest most valuable thing is the PBT2 deal. This is why I think it could explain the whole CR. The investor is the one who wants to control most of the antibiotic-resistant market. The Fund or a big pharma company would qualify as they, for sure, understand this market and may ignore the rest of the issues on my list.
Sorry, I cannot get rid of my "Fund" obsession!
I just wonder if the new investor knows more than we old...
Add ATH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $26.22M | |||
| Open | High | Low | Value | Volume |
| 0.6¢ | 0.6¢ | 0.5¢ | $26.81K | 4.868M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 45 | 42771258 | 0.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.6¢ | 20563308 | 22 |
View Market Depth
| Last trade - 16.10pm 15/05/2024 (20 minute delay) ? |
|
|||||
|
Last
0.5¢ |
Change
0.000 ( 0.00 %) |
||||
| Open | High | Low | Volume | ||
| 0.5¢ | 0.6¢ | 0.5¢ | 1735805 | ||
| Last updated 13.27pm 15/05/2024 ? | |||||
| ATH (ASX) Chart |